Pharma Journalist 8769 posts 0 comments

April 6-8, 2026 | Boston, MA – Against a backdrop of major industry acquisitions including AbbVie/Capstan Therapeutics, Eli Lilly & Co/Verve Therapeutics, and now BMS/Orbital…
Read More...

The European Commission has approved Insmed’s BRINSUPRI (brensocatib 25 mg tablets) as the first and only authorized treatment for non-cystic fibrosis bronchiectasis (NCFB) in the…
Read More...

The U.S. Food and Drug Administration (FDA) has approved AbbVie’s EPKINLY® (epcoritamab-bysp), a subcutaneously administered T-cell engaging bispecific antibody, in combination with…
Read More...

Genprex, Inc. has strengthened the intellectual property protection surrounding its lead drug candidate, REQORSA® Gene Therapy, with the announcement that the U.S. Patent and Trademark…
Read More...

Johnson & Johnson has announced a definitive agreement to acquire Halda Therapeutics OpCo, Inc., a clinical-stage biotechnology company developing next-generation targeted cancer…
Read More...

Biogen announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a unanimous positive opinion recommending approval of a high-dose…
Read More...

Johnson & Johnson has announced a definitive agreement to acquire Halda Therapeutics, a clinical-stage biotech developing oral, targeted cancer therapies using its proprietary…
Read More...

Merus N.V. and Halozyme Therapeutics have entered into a global, non-exclusive collaboration and license agreement to develop and potentially commercialize a subcutaneous formulation of…
Read More...

Solve Therapeutics, a clinical-stage biotechnology company developing best-in-class antibody-drug conjugates (ADCs) for solid tumors, has secured $120 million in an oversubscribed and…
Read More...

Sofinnova Partners, one of Europe’s leading life sciences venture capital firms, has closed its latest flagship fund, Sofinnova Capital XI, at €650 million ($750 million)—substantially…
Read More...